Cluster of differentiation
is a costimulatory protein found on antigen presenting cells
and is required for their activation. The binding of CD154
) on TH cells
to CD40 activates antigen presenting cells and induces a variety of downstream effects.
Deficiency can cause Hyper-IgM syndrome type 3.
The protein receptor encoded by this gene is a member of the TNF-receptor superfamily. This receptor has been found to be essential in mediating a broad variety of immune and inflammatory responses including T cell-dependent immunoglobulin class switching, memory B cell development, and germinal center formation. AT-hook transcription factor AKNA is reported to coordinately regulate the expression of this receptor and its ligand, which may be important for homotypic cell interactions. The TNFR-receptor associated factor adaptor proteins TRAF1, TRAF2, TRAF6 and possibly TRAF5 interact with this receptor serve as mediators of the signal transduction. The interaction of this receptor and its ligand is found to be necessary for amyloid-beta-induced microglial activation, and thus is thought to be an early event in Alzheimer disease pathogenesis. Two alternatively spliced transcript variants of this gene encoding distinct isoforms have been reported.
Specific effects on cells
In the macrophage, the primary signal for activation is IFN-γ from Th1 type CD4 T cells. The secondary signal is CD40L (CD154) on the T cell which binds CD40 on the macrophage cell surface. As a result, the macrophage expresses more CD40 and TNF receptors on its surface which helps increase the level of activation. The increase in activation results in the induction of potent microbicidal substances in the macrophage, including reactive oxygen species and nitric oxide, leading to the destruction of ingested microbe.
The B cell can present antigens to helper T cells. If an activated T cell recognizes the peptide presented by the B cell, the CD40L on the T cell binds to the B cell's CD40 receptor, causing resting B cell activation. The T cell also produces IL-2, which directly influences B cells. As a result of this net stimulation, the B cell can undergo division, antibody isotype switching, and differentiation to plasma cells. The end-result is a B cell that is able to mass-produce specific antibodies against an antigenic target.
Early evidence for these effects were that in CD40 or CD154 deficient mice, there is little class switching or germinal centre formation, and immune responses are severely inhibited.
The expression of CD40 is diverse. CD40 is constitutively expressed by antigen presenting cells, including dendritic cells, B cells and macrophages. It can also be expressed by endothelial cells, smooth muscle cells, fibroblasts and epithelial cells. Consistent with its widespread expression on normal cells, CD40 is also expressed on a wide range of tumor cells, including non-Hodgkin's and Hodgkin's lymphomas, myeloma and some carcinomas including nasopharynx, bladder, cervix, kidney and ovary. CD40 is also expressed on B cell precursors in the bone marrow, and there is some evidence that CD40-CD154 interactions may play a role in the control of B cell haematopoiesis (10)
CD40 (protein) has been shown to interact with TRAF2, TRAF3, TRAF6, TRAF5 and TTRAP.
- ^ "Entrez Gene: CD40 CD40 molecule, TNF receptor superfamily member 5".
- ^ Chatzigeorgiou A, Lyberi M, Chatzilymperis G, Nezos A, Kamper E (2009). "CD40/CD40L signaling and its implication in health and disease". BioFactors (Oxford, England) 35 (6): 474–83. PMID 19904719. doi:10.1002/biof.62.
- ^ McWhirter SM, Pullen SS, Holton JM, Crute JJ, Kehry MR, Alber T (Jul 1999). "Crystallographic analysis of CD40 recognition and signaling by human TRAF2". Proceedings of the National Academy of Sciences of the United States of America 96 (15): 8408–13. PMC 17529. PMID 10411888. doi:10.1073/pnas.96.15.8408.
- ^ a b c d Tsukamoto N, Kobayashi N, Azuma S, Yamamoto T, Inoue J (Feb 1999). "Two differently regulated nuclear factor kappaB activation pathways triggered by the cytoplasmic tail of CD40". Proceedings of the National Academy of Sciences of the United States of America 96 (4): 1234–9. PMC 15446. PMID 9990007. doi:10.1073/pnas.96.4.1234.
- ^ Malinin NL, Boldin MP, Kovalenko AV, Wallach D (Feb 1997). "MAP3K-related kinase involved in NF-kappaB induction by TNF, CD95 and IL-1". Nature 385 (6616): 540–4. PMID 9020361. doi:10.1038/385540a0.
- ^ Hu HM, O'Rourke K, Boguski MS, Dixit VM (Dec 1994). "A novel RING finger protein interacts with the cytoplasmic domain of CD40". The Journal of Biological Chemistry 269 (48): 30069–72. PMID 7527023.
- ^ Ni CZ, Welsh K, Leo E, Chiou CK, Wu H, Reed JC et al. (Sep 2000). "Molecular basis for CD40 signaling mediated by TRAF3". Proceedings of the National Academy of Sciences of the United States of America 97 (19): 10395–9. PMC 27035. PMID 10984535. doi:10.1073/pnas.97.19.10395.
- ^ a b Roy N, Deveraux QL, Takahashi R, Salvesen GS, Reed JC (Dec 1997). "The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases". The EMBO Journal 16 (23): 6914–25. PMC 1170295. PMID 9384571. doi:10.1093/emboj/16.23.6914.
- ^ Ishida TK, Tojo T, Aoki T, Kobayashi N, Ohishi T, Watanabe T et al. (Sep 1996). "TRAF5, a novel tumor necrosis factor receptor-associated factor family protein, mediates CD40 signaling". Proceedings of the National Academy of Sciences of the United States of America 93 (18): 9437–42. PMC 38446. PMID 8790348. doi:10.1073/pnas.93.18.9437.
- ^ Pype S, Declercq W, Ibrahimi A, Michiels C, Van Rietschoten JG, Dewulf N et al. (Jun 2000). "TTRAP, a novel protein that associates with CD40, tumor necrosis factor (TNF) receptor-75 and TNF receptor-associated factors (TRAFs), and that inhibits nuclear factor-kappa B activation". The Journal of Biological Chemistry 275 (24): 18586–93. PMID 10764746. doi:10.1074/jbc.M000531200.
- Carlring J, Altaher HM, Clark S, Chen X, Latimer SL, Jenner T et al. (May 2011). "CD154-CD40 interactions in the control of murine B cell hematopoiesis". Journal of Leukocyte Biology 89 (5): 697–706. PMID 21330346. doi:10.1189/jlb.0310179.
- Parham, Peter (2004). The Immune System (2nd ed.). Garland Science. pp. 169–173. ISBN 0-8153-4093-1.
- Coico R, Sunshine G, and Benjamin E (2003). Immunology: A Short Course. p. 97.
- Clark EA (Jul 1990). "CD40: a cytokine receptor in search of a ligand". Tissue Antigens 36 (1): 33–6. PMID 1701063. doi:10.1111/j.1399-0039.1990.tb01795.x.
- Banchereau J, Bazan F, Blanchard D, Brière F, Galizzi JP, van Kooten C et al. (1994). "The CD40 antigen and its ligand". Annual Review of Immunology 12: 881–922. PMID 7516669. doi:10.1146/annurev.iy.12.040194.004313.
- van Kooten C, Banchereau J (Jan 2000). "CD40-CD40 ligand". Journal of Leukocyte Biology 67 (1): 2–17. PMID 10647992.
- Schattner EJ (May 2000). "CD40 ligand in CLL pathogenesis and therapy". Leukemia & Lymphoma 37 (5-6): 461–72. PMID 11042507. doi:10.3109/10428190009058499.
- Bhushan A, Covey LR (2002). "CD40:CD40L interactions in X-linked and non-X-linked hyper-IgM syndromes". Immunologic Research 24 (3): 311–24. PMID 11817328. doi:10.1385/IR:24:3:311.
- Cheng G, Schoenberger SP (2002). "CD40 signaling and autoimmunity". Current Directions in Autoimmunity. Current Directions in Autoimmunity 5: 51–61. ISBN 3-8055-7308-1. PMID 11826760. doi:10.1159/000060547.
- Dallman C, Johnson PW, Packham G (Jan 2003). "Differential regulation of cell survival by CD40". Apoptosis : An International Journal on Programmed Cell Death 8 (1): 45–53. PMID 12510151. doi:10.1023/A:1021696902187.
- O'Sullivan B, Thomas R (Jul 2003). "Recent advances on the role of CD40 and dendritic cells in immunity and tolerance". Current Opinion in Hematology 10 (4): 272–8. PMID 12799532. doi:10.1097/00062752-200307000-00004.
- Benveniste EN, Nguyen VT, Wesemann DR (Jan 2004). "Molecular regulation of CD40 gene expression in macrophages and microglia". Brain, Behavior, and Immunity 18 (1): 7–12. PMID 14651941. doi:10.1016/j.bbi.2003.09.001.
- Xu Y, Song G (2005). "The role of CD40-CD154 interaction in cell immunoregulation". Journal of Biomedical Science 11 (4): 426–38. PMID 15153777. doi:10.1159/000077892.
- Contin C, Couzi L, Moreau JF, Déchanet-Merville J, Merville P (2004). "[Immune dysfuntion of uremic patients: potential role for the soluble form of CD40]". Néphrologie 25 (4): 119–26. PMID 15291139.